1 / 8

No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion

CREATE-ECLA - GIK Trial. No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion. Presented at: American Heart Association Scientific Sessions 2004 Presented by: Dr. S.R. Mehta. CREATE-ECLA - GIK.

sharis
Download Presentation

No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CREATE-ECLA - GIK Trial No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion Presented at: American Heart Association Scientific Sessions 2004 Presented by: Dr. S.R. Mehta

  2. CREATE-ECLA - GIK 20,195 patients with acute ST-segment-elevation MI presenting within 12 hours of symptom onset 77.8% male, mean age 58.6 9% received PCI, 74% thrombolytic therapy 97% Aspirin, 72% ACE inhibitors, 70% beta-blockers, 68% lipid-lowering therapy Also randomized to reviparin or placebo – results presented separately • GIK • Infusion of high-dose GIK (25% glucose, 50 units/L insulin, and 80 mEq/L KCI) for 24 hours at 1.5 mL/kg per hour • n=10,088 Mean onset-to-treatment = 4.6 hr • Usual Care • n=10,107 Mean onset-to-treatment = 4.7 hr Primary Endpoint: 30 day mortality Secondary Endpoints: 30 day cardiac arrest, cardiogenic shock, reinfarction, Safety Endpoints: Pulmonary edema, Heart failure, Killip class > 1, Hyperkalemia, Significant phlebitis, Hypoglycemia Presented at AHA 2004

  3. CREATE-ECLA – GIK: Primary endpoint 30 DAY MORTALITY p = 0.45 • No difference in 30-day mortality between the GIK and control groups % Presented at AHA 2004

  4. CREATE-ECLA –GIK: Secondary endpoint No difference in the secondary endpoints of cardiac arrest, cardiogenic shock or reinfarction between the two groups p=0.38 p=0.81 p=0.51 % Presented at AHA 2004

  5. CREATE-ECLA – GIK: Ischemia Recurrent Ischemia at 7 days p = 0.004 • GIK was associated with a significant reduction in recurrent ischemia at 7 days. The reduction remained significant at 30 days (p=0.036) • Recurrent ischemia was neither a primary nor secondary endpoint % Presented at AHA 2004

  6. CREATE-ECLA –GIK: Safety endpoints No difference in incidence of pulmonary edema, heart failure or worse Killip class between the two groups p=0.88 p=0.92 p=0.42 % Presented at AHA 2004

  7. CREATE-ECLA –GIK: Safety endpoints p=0.0006 p=<0.0001 p=<0.0001 % Presented at AHA 2004

  8. CREATE-ECLA –GIK: Summary • Among acute MI patients presenting within 12 hours of onset of symptoms, treatment with a high-dose glucose-insulin-potassium infusion was not associated with a difference in the primary endpoint of 30-day mortality compared with control. • In addition, the two groups showed no difference in the secondary endpoints of cardiac arrest, cardiogenic shock, and reinfarction at 30 days. • GIK was associated with a reduction in recurrent ischemia at 7 and 30 days, but an increase in hyperkalemia, phlebitis and hypoglycemia. • These findings differ from a previous meta-analysis of 16 smaller studies, which suggested a reduction in mortality with GIK.

More Related